Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Multicenter Prospective Phase II Study of Rituximab Combined, Bortezomib, Lenalidomide, Dexamethasone Followed By Lenalidomide Maintenance (R-VRD) in Patients with Waldenstrom's Macroglobulinemia (KMM1803)

Ho Sup Lee, Dajung Kim, Sung-Hoon Jung, Je-Jung Lee, Kihyun Kim, Chang-Ki Min, Jae Hoon Lee, Won-Sik Lee, JiHyun Lee, Gyeong Won Lee, Min Kyoung Kim, Ho-Jin Shin, Hyo Jung Kim, Jun Ho Yi

Blood (2023) 142 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2023-180325

Published: 2023

Journal Articles

A Novel PI3K γ/δ and DNA-PK Triple Inhibitor, BR101801, for r/r PTCL: A Phase 1a/b, Multi-Center, Open-Label Clinical Trial

Bong-Seog Kim, Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Tae Min Kim, Eunyoung Lee, Jeong-Ok Lee, Deok-Hwan Yang, Won-Sik Lee

Blood (2023) 142 (Supplement 1): 1701.

https://doi.org/10.1182/blood-2023-173010

Published: 2023

Journal Articles

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data

Swami P. Iyer, Sabarish R. Ayyappan, Irl Brian Greenwell, Won Seog Kim, Seung Tae Lee, Jin Seok Kim, Won-Sik Lee, Youngwoo Jeon, William Johnson, Utpal P. Dave, Sung-Soo Yoon, Ka-Won Kang, Florent Carrette, Julien Viotti, A.J. Leyco, Marianna Muller, Steven M. Horwitz

Blood (2023) 142 (Supplement 1): 3072.

https://doi.org/10.1182/blood-2023-172537

Published: 2023

Journal Articles

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Blood (2023) 142 (Supplement 1): 6675.

https://doi.org/10.1182/blood-2023-174439

Published: 2023

Journal Articles

Safety and Effectiveness of Rituximab Biosimilar CT-P10 during Routine Clinical Practice: Final Analysis of a Post-Marketing Surveillance Study in the Republic of Korea

Seok-Goo Cho, Jae-Cheol Jo, Young-Woo Jeon, Dajung Kim, Deok-Hwan Yang, Won Sik Lee, Yoon Seok Choi, Jun Ho Yi, Dok Hyun Yoon, Jee Hyun Kong, Jung-yoon Choe, Sung Hyun Kim, Keum Young Ahn, TaeHong Park, Jeongah Park, Sangeun Han

Blood (2022) 140 (Supplement 1): 10960–10962.

https://doi.org/10.1182/blood-2022-156478

Published: 2022

Journal Articles

Risk Stratification for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Simplified Geriatric Assessment: A Prospective, Multicenter, Cohort Study

Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Chang-Hoon Lee, Ga-Young Song, Jae-Yong Kwak, Deok-Hwan Yang

Blood (2022) 140 (Supplement 1): 6719–6720.

https://doi.org/10.1182/blood-2022-159929

Published: 2022

Journal Articles

Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma

Yuqin Song, Won-Seog Kim, Dok-Hyun Yoon, Haiyan Yang, Junning Cao, Dongmei Ji, Youngil Koh, Hongmei Jing, Hyeon-Seok Eom, Jae-Yong Kwak, Won-Sik Lee, Jong-Seok Lee, Ho-Jin Shin, Jie Jin, Mei Wang, Jingrun Li, Jun Zhu

Blood (2022) 140 (Supplement 1): 6545–6546.

https://doi.org/10.1182/blood-2022-162947

Published: 2022

Journal Articles

Aryl hydrocarbon receptor–targeted therapy for CD4 + T cell–mediated idiopathic pneumonia syndrome in mice

Soung-Min Lee, Chae Eun Kim, Ha Young Park, Eun Hye Yoon, Hae Jeong Won, Joo Mi Ahn, Nu Zen Na Nguyen, Minji Kim, Won Hee Jang, Won-Sik Lee, Mi Seon Kang, Myeonggyo Jeong, Hwayoung Yun, Suhyun Park, Sangwook Wu, Dong Hyun Kim, Byungsuk Kwon, Su-Kil Seo

Blood (2022) 139 (22): 3325–3339.

https://doi.org/10.1182/blood.2021013849

Published: 2022

Includes: Supplemental data

Journal Articles

Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease

Dong Won Baek, Sr., Joon Ho Moon, Jae-Sook Ahn, Seong Kyu Park, Ik Chan Song, Ho-Sup Lee, Won Sik Lee, Jong Ho Won, Hong Ghi Lee, June-Won Cheong, Yeung-Chul Mun, Chul W. Jung, Je-Hwan Lee, Hyeoung-Joon Kim, Sang Kyun Sohn

Blood (2021) 138 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2021-154470

Published: 2021

Journal Articles

Clinical Response Evaluation Toward Individualizing the Starting Dose of Dasatinib in Asian Patients with Chronic Myeloid Leukemia

Hyejin Shin, Jung-Eun Ha, Dae Young Zang, MDPhD, Sung-Hyun Kim, MD PhD, Young Rok Do, PhDMD, Won Sik Lee, MD PhD, Soo-Hyun Kim, Kyung-Mi Kee, Seon-Young Yang, So-Yoon Hwang, Eun-Jung Jang, Jangik Lee, PharmD, Dong-Wook Kim, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-140626

Published: 2020

Journal Articles

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Sung-Eun Lee, MD PhD, Joon Seong Park, MD, Young Rok Do, PhDMD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Jae-Yong Kwak, Jeong-A Kim, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Dong-Wook Kim, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139253

Published: 2020

Journal Articles

A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T- Cell Lymphoma

Won-Seog Kim, Dok-Hyun Yoon, MD PhD, Hyeon-Seok Eom, Youngil Koh, Jae-Yong Kwak, Won-Sik Lee, Jong-Seok Lee, Ho-Jin Shin, Yuqin Song, MD PhD, Haiyan Yang, MD PhD, Mei Wang, Jingrun Li, MDPhD, Xubin Huang, Xueyuan Deng, Kan Chen, Zhenfan Yang, Jun Zhu

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-134650

Published: 2020

Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim

Blood (2019) 134 (Supplement_1): 1643.

https://doi.org/10.1182/blood-2019-126376

Published: 2019

Journal Articles

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Blood (2019) 134 (Supplement_1): 2844.

https://doi.org/10.1182/blood-2019-129664

Published: 2019

Journal Articles

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Jae-Cheol Jo, MD, Ho Sup Lee, MD, Cheolwon Suh, Hye Jin Kang, MD PhD, Won Seog Kim, MD PhD, HyeonSeok Eom, MD PhD, Inho Kim, MD PhD, Ho-Jin Shin, MD PhD, Yong Park, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Lee Gyeong-Won, Sung Yong Oh, Sung-Nam Lim, MD, Seong Yoon Lee, MD

Blood (2019) 134 (Supplement_1): 2884.

https://doi.org/10.1182/blood-2019-132192

Published: 2019

Journal Articles

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Ga-Young Song, Seok Jin Kim, MD PhD, Sang Eun Yoon, Jin Seok Kim, MD PhD, Ho-Young Yhim, MD PhD, Youngil Koh, MD PhD, Sung Yong Oh, MD PhD, Ho Sup Lee, MD PhD, Ho-Jin Shin, MD PhD, Young Rok Do, MD PhD, Won Sik Lee, MD PhD, Lee Gyeong-Won, Dae Sik Kim, Yong Park, Deok-Hwan Yang, MD PhD

Blood (2019) 134 (Supplement_1): 4002.

https://doi.org/10.1182/blood-2019-126574

Published: 2019

Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Blood (2019) 134 (Supplement_1): 4035.

https://doi.org/10.1182/blood-2019-126637

Published: 2019

Journal Articles

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Yukio Kobayashi, Iekuni Oh, MD PhD, Toshihiro Miyamoto, MD PhD, Won-Sik Lee, Hiroatsu Iida, MD PhD, Hironobu Minami, MD PhD, Yoshinobu Maeda, MD PhD, Jun Ho Jang, Sung-Soo Yoon, MD PhD, Su-Peng Yeh, MD, Qui Tran, Joan Morris, Janet L. Franklin, Ka-Wing Chong, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 5069.

https://doi.org/10.1182/blood-2019-124582

Published: 2019

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y

Hawk Kim, MD PhD, Yunsuk Choi, MD, Sung-Soo Yoon, MD PhD, Soo-Mee Bang, MD PhD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Yeung-Chul Mun, Young Rok Do, PhD MD, Yong Park, MD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Ho Sup Lee, MD, Min Kyoung Kim, MD PhD, Won-Sik Lee, Jeong-Yeal Ahn, MD, Kyoo-Hyung Lee, MD PhD

Blood (2018) 132 (Supplement 1): 3876.

https://doi.org/10.1182/blood-2018-99-116190

Published: 2018

Journal Articles

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Yoojin Lee, MD PhD, Kihyun Kim, MD PhD, Sang Kyun Sohn, MDPhD, Dongwon Back, MD, Joon Ho Moon, MD, Je-Jung Lee, MD PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Min Kyoung Kim, MD PhD, Ho Sup Lee, MD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2018-99-113229

Published: 2018

NARROW

Multicenter Prospective Phase II Study of Rituximab Combined, Bortezomib, Lenalidomide, Dexamethasone Followed By Lenalidomide Maintenance (R-VRD) in Patients with Waldenstrom's Macroglobulinemia (KMM1803)

A Novel PI3K γ/δ and DNA-PK Triple Inhibitor, BR101801, for r/r PTCL: A Phase 1a/b, Multi-Center, Open-Label Clinical Trial

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Safety and Effectiveness of Rituximab Biosimilar CT-P10 during Routine Clinical Practice: Final Analysis of a Post-Marketing Surveillance Study in the Republic of Korea

Risk Stratification for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Simplified Geriatric Assessment: A Prospective, Multicenter, Cohort Study

Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma

Aryl hydrocarbon receptor–targeted therapy for CD4 + T cell–mediated idiopathic pneumonia syndrome in mice

Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease

Clinical Response Evaluation Toward Individualizing the Starting Dose of Dasatinib in Asian Patients with Chronic Myeloid Leukemia

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T- Cell Lymphoma

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only